• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1 infected Thais

An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1 infected Thais

by Adam | Oct 22, 2016

AIDS Research and Human Retroviruses 2001; 17(8):703-18.
Designing HIV-1 vaccines to reflect viral diversity and the global context of HIV/AIDS

Designing HIV-1 vaccines to reflect viral diversity and the global context of HIV/AIDS

by Adam | Oct 22, 2016

AIDScience 1(2) June 22, 2001.
Rapid Determination of HLA B*07- ligands from the West Nile Virus genome

Rapid Determination of HLA B*07- ligands from the West Nile Virus genome

by Adam | Oct 22, 2016

Emerging Infectious Diseases, Vol. 7, No. 4, July–August 2001: 706-713.
From genome to vaccine: In silico predictions, ex vivo verification

From genome to vaccine: In silico predictions, ex vivo verification

by Adam | Oct 22, 2016

Vaccine 2001 Aug 14; 19(31):4385-95.
Use of T cell epitopes for vaccine development

Use of T cell epitopes for vaccine development

by Adam | Oct 22, 2016

Current Drug Targets – Infectious Disorders, 2001, 1, 283-293.

Recent Posts

  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic
  • EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide
  • Doing Well and Giving Back in December

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.